Lipocine Inc. (LPCN) Fundamentals

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO, is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
SHARE INFORMATION
Market Cap$ 68,763,819
Shares Outstanding88,499,124
Float86,212,211
Percent Float97.42%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 16,140,838
Latest Fiscal EPS$ -0.01
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions79
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months491,728
Institutional Holdings Percent24.2%
Institutional Sold Previous 3 Months664,539
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months287,500
Insider Holdings Percent3.5
Insider Sold Previous 3 Months-
Insider Shares Owned3,123,221
TRADING INFO
52 Week High$ 1.89
52 Week Low$ 0.71
52 Week High Change$ -37.84
21 Day Moving Average$ 0.896
21 Day Extended Moving Average$ 0.908254
50 Day Moving Average$ 1.2211
50 Day Extended Moving Average$ 1.0644
200 Day Moving Average$ 1.161
200 Day Extended Moving Average$ 1.181
10 Day Average Volume383,395
20 Day Average Volume477,901
30 Day Average Volume592,284
50 Day Average Volume952,902
Alpha0.007740
Beta0.5027
Standard Deviation0.241058
R20.009744
7 Day Price Change$ -0.0333
7 Day Percent Change-4.11%
21 Day Price Change$ -0.2102
21 Day Percent Change-21.29%
30 Day Price Change$ -0.343
30 Day Percent Change-30.63%
Month to Date Price Change$ -0.1049
Month to Date Percent Change-11.89%
Quarter to Date Price Change$ -0.593
Quarter to Date Percent Change-43.28%
180 Day Price Change$ -0.413
180 Day Percent Change-34.71%
200 Day Price Change$ -0.263
200 Day Percent Change-25.29%
Year to Date Price Change$ -0.2141
Year to Date Percent Change-21.6%

Lipocine Inc. (LPCN) Key Ratios

PROFITABILITY
EBIT Margin-3.7%
EBITDA Margin-3.7%
Pre-Tax Profit Margin0.0%
Profit Margin Count-4.63%
Gross Margin63.3%
Profit Margin TOT-4.63%
INCOME STATEMENTS
Revenue$ 16,140,838
Revenue Per Share$ 0.1824
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.60
Total Debt To Equity0.00
Int Coverage-3.90
Current Ratio12.40
Leverage Ratio1.20
Quick Ratio12.00
Long Term Debt To Capital0.03
VALUATION MEASURES
PE Ratio-77.70
Enterprise Value$ 28,246,454
Price to Sales4.2602
Price to Free Cash-16.10
PE High Last 5 Years-3.50
Price To Book1.60
Price To Cash Flow0.00
PE Low Last 5 Years-3.10
Price to Tangible Book1.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover261.00
Invoice Turnover0.00
Assets Turnover0.40
Return Assets-1.58
Return on Equity-1.83
Return on Capital-1.61

Lipocine Inc. (LPCN) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorTanner LLC
CEOMahesh V. Patel
Emplyoees13
Last AuditUQ
CIK0001535955
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address675 Arapeen Drive
Suite 202
Salt Lake City, UT 84108
Websitehttp://www.lipocine.com
Facsimile+1 801 994-7388
Telephone+1 801 994-7383
Emailmb@lipocine.com


Your Recent History
NASDAQ
LPCN
Lipocine
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.